No statistically significant differences in secondary outcomes were seen at any time. Background: No drug treatments are currently licensed for the treatment of borderline personality disorder (BPD). Trial registration: Current Controlled Trials ISRCTN90916365. Participants: Between July 2013 and October 2015 we randomised 276 participants, of whom 195 (70.6%) were followed up 52 weeks later. La lamotrigina è un farmaco che negli ultimi anni è stato utilizzato per la cura di questo disturbo, sebbene… 7. J Affect Disord. No drug treatments are currently licensed for the treatment of borderline personality disorder (BPD). Potential participants had to be aged ≥ 18 years, meet diagnostic criteria for BPD and provide written informed consent. Etwa 50 Prozent der Borderline-Patienten sprechen auf die angebotenen Therapieformen beim ersten Behandlungsversuch an. Participants were randomised via an independent and remote web-based service using permuted blocks and stratified by study centre, the severity of personality disorder and the extent of hypomanic symptoms. About 78% of adults with BPD also develop a substance-related disorder or addiction at some time in their lives. Future work: Dadurch führt die Borderline-Störung oft zu erheblichen Belastungen und kann sowohl die Lebensqualität der Betroffenen als auch ihrer Bezugspersonen stark reduzieren. 17. Women taking combined oral contraceptives were prescribed up to 400 mg of trial medication per day. Limitations: Participants: Potential participants had to be aged ≥ 18 years, meet diagnostic criteria for BPD and provide written informed consent. Lamotrigin Aurobindo gehört zu einer Gruppe von Arzneimitteln, die als Antiepileptika bezeichnet werden. Alan Montgomery is part of the HTA Clinical Evaluation and Trials Board. 17. Part of Richard Morriss’ salary during the project was paid by NIHR Collaboration for Leadership in Applied Health Research and Care East Midlands. Lamotrigine is a member of the class of 1,2,4-triazines in which the triazene skeleton is substituted by amino groups at positions 3 and 5, and by a 2,3-dichlorophenyl group at position 6. Come sopra accennato, la lamotrigina ha anche una azione stabilizzante sull’umore, e per la precisione è il primo farmaco, dopo il litio, ad aver ottenuto il riconoscimento “on label” per il trattamento del disturbo bipolare. Conclusions: The Imperial Biomedical Research Centre Facility, which is funded by NIHR, also provided support that has contributed to the research results reported within this paper. The secondary outcomes were depressive symptoms, deliberate self-harm, social functioning, health-related quality of life, resource use and costs, side effects of treatment and adverse events. Bei der Behandlung der Epilepsie wirkt Lamotrigin Aristo® durch Hemmung der Signale im Gehirn, die die epileptischen Anfälle auslösen. Health Technology Assessment Stimmungsschwankungen, impulsives Verhalten, anhaltende Schwierigkeiten im Umgang mit anderen Menschen, Selbstverletzung – all dies sind mögliche Symptome der Borderline … In un recente editoriale pubblicato nella rivista scientifica The American Journal of Psychiatry (agosto 2018), gli autori Gunderson e Choi-Kain hanno effettuato una riflessione sulle attuali conoscenze sulla terapia farmacologia del disturbo borderline di personalità (BPD). Funding for this trial was provided by the Health Technology Assessment programme of the National Institute for Health Research (NIHR) and will be published in full in Health Technology Assessment; Vol. Dieses Bild hat sich mit der Entwicklung speziell auf Borderliner zugeschnittener Therapien erheblich gewandelt. Setting: Secondary care NHS mental health services in six centres in England. 8. Trials. Lamotrigine is not effective for the treatment of borderline personality disorder. Anders ausgedrückt: Sie leiden unter einem geringen Selbstwert und einem anhaltendes Gefühl innerer Leere. People were excluded if they met criteria for bipolar disorder or a psychotic disorder. Il Litio e la Lamotrigina sono raccomandati come trat-tamento iniziale per la depressione bipolare I acuta 11 12. Lamotrigine Ineffective in Borderline Personality Disorder. Am J Psychiatry. 22, No. A two-arm, double-blind, placebo-controlled individually randomised trial of lamotrigine versus placebo. Women taking combined oral contraceptives were prescribed up to 400 mg of trial medication per day. Objective: To examine the clinical effectiveness and cost-effectiveness of lamotrigine for people with BPD. An automated randomisation system was used and everyone received ‘treatment as usual’ except that they couldn’t be prescribed another mood stabiliser or have an additional lamotrigine prescription. At 52 weeks, 49 (36%) of those participants prescribed lamotrigine and 58 (42%) of those prescribed placebo were taking it. Funding: Funding for this trial was provided by the Health Technology Assessment programme of the National Institute for Health Research (NIHR) and will be published in full in Health Technology Assessment; Vol. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Es wird bei zwei Krankheitsbildern angewendet — Epilepsie und bipolare Störung. Please enable it to take advantage of the complete set of features! Current Controlled Trials ISRCTN90916365. Main outcome measures: Borderline-Patienten wissen häufig gar nicht, wer sie selber wirklich sind oder wer sie sein möchten. Institutions for all authors have received funding from the National Institute for Health Research for other studies. Up to 200 mg of lamotrigine per day or an inert placebo. Dursun SM, Deakin JF. (2018-04-01). Setting: Despite this, people with this condition are frequently prescribed psychotropic medications and often with considerable polypharmacy. Bei der Behandlung der Epilepsie wirkt Lamotrigin Aurobindo durch Hemmung der Signale im … Lamotrigina disturbo bipolare. This site needs JavaScript to work properly. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. Future work: Future research into the treatment of BPD should focus on improving the evidence base for the clinical effectiveness and cost-effectiveness of non-pharmacological treatments to help policy-makers make better decisions about investing in specialist treatment services. Der Wirkstoff ist im Allgemeinen gut verträglich. 10/103/01/DH_/Department of Health/United Kingdom, Spiral, Imperial College Digital Repository. Lamotrigin gehört zu den Antiepileptika der zweiten Generation und wird vor allem zur Therapie von Epilepsien, aber auch bei bipolaren Störungen, angewendet. April 20, 2018. This website uses cookies to ensure you get the best experience. Efficacy and Tolerability of Lamotrigine in Borderline Personality Disorder: A Systematic Review and Meta-Analysis. We excluded people with coexisting psychosis or bipolar affective disorder, those already taking a mood stabiliser, those who spoke insufficient English to complete the baseline assessment and women who were pregnant or contemplating becoming pregnant. The Clinical Effectiveness and Cost-Effectiveness of Lamotrigine in Borderline Personality Disorder: A Randomized Placebo-Controlled Trial. Interventions: Levels of adherence in this pragmatic trial were low, but greater adherence was not associated with better mental health. We excluded people with coexisting psychosis or bipolar affective disorder, those already taking a mood stabiliser, those who spoke insufficient English to complete the baseline assessment and women who were pregnant or contemplating becoming pregnant. See the NIHR Journals Library website for further project information. Results: Between July 2013 and October 2015 we randomised 276 participants, of whom 195 (70.6%) were followed up 52 weeks later. Bei dieser Persönlichkeitsstörung sind bestimmte Vorgänge in den Bereichen Gefühle, Denken und Handeln beeinträchtigt. Mood stabilizers like lamotrigine are intended … Funding for this trial was provided by the Health Technology Assessment programme of the National Institute for Health Research (NIHR) and will be published in full in Health Technology Assessment; Vol. Stoffers-Winterling J, Storebø OJ, Lieb K. Curr Psychiatry Rep. 2020 Jun 5;22(8):37. doi: 10.1007/s11920-020-01164-1. 2016 Jul;20(52):1-250. doi: 10.3310/hta20520. Preliminary studies have indicated that mood stabilisers may be of benefit to people with BPD. Borderline-Syndrom: Krankheitsverlauf und Prognose. Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCT. McMurran M, Crawford MJ, Reilly J, Delport J, McCrone P, Whitham D, Tan W, Duggan C, Montgomery AA, Williams HC, Adams CE, Jin H, Lewis M, Day F. Health Technol Assess. Joseph G Reilly has received project funding from the Drug Safety Research Unit as part of an unrestricted grant provided by Merck Pharmaceuticals. Learn more about DOAJ’s privacy policy. The primary outcome was the total score on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) at 52 weeks. Pazienti borderline spesso visualizzare l'aggressione patologica. Trial registration: Duffy L, Lewis G, Ades A, Araya R, Bone J, Brabyn S, Button K, Churchill R, Croudace T, Derrick C, Dixon P, Dowrick C, Fawsitt C, Fusco L, Gilbody S, Harmer C, Hobbs C, Hollingworth W, Jones V, Kendrick T, Kessler D, Khan N, Kounali D, Lanham P, Malpass A, Munafo M, Pervin J, Peters T, Riozzie D, Robinson J, Salaminios G, Sharp D, Thom H, Thomas L, Welton N, Wiles N, Woodhouse R, Lewis G. Southampton (UK): NIHR Journals Library; 2019 Dec. Osborn D, Burton A, Walters K, Atkins L, Barnes T, Blackburn R, Craig T, Gilbert H, Gray B, Hardoon S, Heinkel S, Holt R, Hunter R, Johnston C, King M, Leibowitz J, Marston L, Michie S, Morris R, Morris S, Nazareth I, Omar R, Petersen I, Peveler R, Pinfold V, Stevenson F, Zomer E. Southampton (UK): NIHR Journals Library; 2019 Apr. Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT. Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies. 22, No. Outcomes were assessed at 12, 24 and 52 weeks after randomisation. 17. At 52 weeks, 49 (36%) of those participants prescribed lamotrigine and 58 (42%) of those prescribed placebo were taking it. Funding: The secondary outcomes were depressive symptoms, deliberate self-harm, social functioning, health-related quality of life, resource use and costs, side effects of treatment and adverse events. Copyrights and related rights for article metadata waived via CC0 1.0 Universal (CC0) Public Domain Dedication. User Reviews for Lamotrigine to treat Borderline Personality Disorder. Lamotrigine, a mood-stabilising drug, is not clinically effective for the treatment of borderline personality disorder. Adjusted costs of direct care for those prescribed lamotrigine were similar to those prescribed placebo. The primary outcome was the total score on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) at 52 weeks. Lebensjahr zugelassen. Participants were randomised via an independent and remote web-based service using permuted blocks and stratified by study centre, the severity of personality disorder and the extent of hypomanic symptoms. At 52 weeks, the mean total ZAN-BPD score was 11.3 [standard deviation (SD) 6.6] among those participants randomised to lamotrigine and 11.5 (SD 7.7) among those participants randomised to placebo (adjusted mean difference 0.1, 95% CI -1.8 to 2.0; p = 0.91). Bethesda, MD 20894, Copyright Background: Borderline personality disorder (BPD) is a disabling psychiatric condition with a chronic and challenging course. [1][2] BPS hat auch erhebliche Auswirkungen auf Paarbeziehung… Background: Borderline personality disorder (BPD) patients, when in crisis, are frequent visitors of emergency departments (EDs).